|2.||Coronary Disease (Coronary Heart Disease)
|3.||Peripheral Arterial Disease
|4.||Bacterial Infections (Bacterial Infection)
|1.||Jeong, Myung Ho: 13 articles (01/2016 - 12/2004)|
|2.||Hong, Young Joon: 12 articles (03/2015 - 12/2004)|
|3.||Kim, Ju Han: 9 articles (03/2015 - 12/2004)|
|4.||Lim, Kyung Seob: 8 articles (01/2016 - 05/2010)|
|5.||Sim, Doo Sun: 8 articles (03/2015 - 05/2010)|
|6.||Cho, Jeong Gwan: 8 articles (03/2015 - 12/2004)|
|7.||Ahn, Youngkeun: 8 articles (03/2015 - 10/2007)|
|8.||Park, Jong Chun: 8 articles (03/2015 - 12/2004)|
|9.||Kim, Jung Ha: 7 articles (03/2015 - 05/2010)|
|10.||Kang, Jung Chaee: 7 articles (11/2011 - 12/2004)|
|1.||Sirolimus (Rapamycin)FDA Link
07/20/2005 - "Recently, preliminary data of the ORBIT study have been presented; coronary restenosis after oral treatment with sirolimus (SRL) was merely 7.7%. "
12/01/2012 - "Rapamycin (Sirolimus®) is used to prevent rejection of transplanted organs and coronary restenosis. "
11/01/2005 - "To assess the role of oral rapamycin in the prevention of coronary restenosis in patients undergoing coronary stenting. "
06/01/2005 - "Finally, new antiproliferative agents, such as oral rapamycin, have been introduced to reduce the rate of coronary restenosis during follow-up."
09/01/2009 - "Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results."
|2.||Paclitaxel (Taxol)FDA LinkGeneric
05/01/2010 - "The purpose of this study was to evaluate the Genous(TM) endothelial progenitor cell capturing stent vs. the Taxus Liberté paclitaxel-eluting stent in patients with de novo coronary lesions with a high-risk of coronary restenosis. "
03/01/2013 - "[Paclitaxel-coated balloon catheter in coronary restenosis?]."
05/01/2009 - "Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model."
07/01/2007 - "After elective paclitaxel-eluting stent implantation, there is no difference in coronary restenosis in younger and elderly patients, suggesting an age-independent efficacy."
07/01/2007 - "We sought to evaluate the impact of paclitaxel-eluting stents on coronary restenosis in elderly patients undergoing elective PCI. "
|3.||tranilast (N 5')IBA
01/11/1996 - "These results suggest that tranilast may be effective in preventing coronary restenosis."
04/01/1997 - "In a recent clinical study, tranilast, an anti-allergic agent, was shown to reduce the rate of coronary restenosis after percutaneous transluminal coronary angioplasty, although the mechanism of this effect is unclear. "
06/18/1997 - "These results suggest that tranilast inhibits the contraction of vascular smooth muscle by inhibiting Ca2+ mobilization, which might be related to its preventive effect on coronary restenosis after percutaneous transluminal coronary angioplasty."
06/18/1997 - "Recently, the anti-allergic drug tranilast has been shown to reduce the rate of coronary restenosis after percutaneous transluminal coronary angioplasty. "
|4.||abciximab (ReoPro)FDA Link
01/01/2006 - "Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio."
12/01/2004 - "A ReoPro-coated stent is safe, and may be effective in the prevention of coronary restenosis."
10/01/2007 - "Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model."
03/07/2006 - "Recently we have demonstrated that abciximab-coated stents have inhibitory effects in the prevention of coronary restenosis. "
12/01/2004 - "Previously, the inhibition of coronary restenosis with Abciximab (ReoPro)-coated stent in a porcine model was reported. "
01/01/2008 - "Although restenosis after successful coronary stenting is associated with changes in adhesion molecules and chemokines, it is unclear whether the differential effects of these molecules between a bare metal stent (BMS) and sirolimus-eluting stent (SES) may help to prevent coronary restenosis. "
|7.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
|8.||docetaxel (Taxotere)FDA Link
|9.||Probucol (Lorelco)FDA Link
03/01/2002 - "The antioxidant probucol reduced coronary restenosis in the MultiVitamins and Probucol (MVP) trial by improving vascular remodelling. "
02/06/2003 - "The powerful antioxidant probucol has been shown to prevent coronary restenosis after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial and other clinical studies. "
01/01/2002 - "The powerful antioxidant probucol has been shown to prevent coronary restenosis after balloon angioplasty in the Multivitamins and Probucol (MVP) trial and other clinical studies. "
07/01/2000 - "Probucol has been shown to prevent coronary restenosis after balloon angioplasty in clinical trials. "
02/01/2012 - "Probucol has anti-atherosclerotic properties and has been shown to reduce post-angioplasty coronary restenosis. "
|10.||glucuronyl glucosamine glycan sulfate (Vessel)IBA
02/01/1992 - "This study was thus performed to determine the relation between severity of vessel wall injury and the thickness of resulting neointimal proliferation in a porcine model of coronary restenosis. "
03/26/2011 - "Since the introduction of DES, coronary restenosis as well as the incidence of target vessel and target lesion revascularization have been significantly reduced. "
01/01/2006 - "BMS, to reduce coronary restenosis -- at least for higher risk patients undergoing single-vessel revascularization."
09/01/1997 - "In this single-center study, intracoronary blood flow and Doppler-derived coronary flow reserve immediately postpercutaneous transluminal coronary angioplasty were not predictive of long-term vessel patency or late coronary restenosis. "
03/01/1992 - "In total, MTS at 6 months had the best sensitivity for the detection of coronary restenosis after single vessel angioplasty and an excellent negative predictive value (96% alone, 100% combined with ET), eliminating the need for coronary arteriography when it is negative."
04/01/2009 - "Drug-eluting coronary stent implantation emerged as a safe and effective therapeutic approach by preventing coronary restenosis and reducing the need for further revascularization. "
12/01/2009 - "In spite of all randomized studies with oral therapies in the bare metal stent (BMS) era demonstrating positive reductions in coronary restenosis, this practice has not been introduced clinically. "
09/01/2005 - "The aim of the present study was to evaluate the influence of genetic risk factors combined with the conventional risk factors on the development of coronary restenosis after percutaneous coronary intervention (PCI) with stent implantation. "
01/01/2003 - "The year 2002 was marked elsewhere by imagination after the publication of the RAVEL study on coated stents delivering anti-proliferative drugs in order to avoid coronary restenosis. "
11/01/2002 - "In this study, we have examined the implication of this polymorphism with regard to coronary restenosis after Palmaz-Schatz stent deployment. "
|2.||Angioplasty (Angioplasty, Transluminal)
07/01/1993 - "Impaired regional left ventricular function has been shown to improve after successful transluminal coronary angioplasty, but there are no data concerning the effect of coronary restenosis on this recovery. "
01/01/2003 - "We cultured smooth muscle cells (SMCs) from specimens obtained from 24 patients with coronary restenosis after angioplasty to study the relationship between activity of SMCs (in vitro outgrowth) and the time course of restenosis. "
11/01/1999 - "In parallel, anatomopathological studies of post-angioplasty coronary restenosis show histological appearances similar to those observed in patients with severe hyper-homocysteinaemia. "
10/01/1999 - "Although studies with more patients are required, a combined lipid lowering and antioxidant therapy could achieve a reduction in angioplasty coronary restenosis."
02/01/1989 - "Coronary restenosis occurs fairly early after transluminal coronary angioplasty, as suggested by anatomico-clinical, isotopic and angiographic studies. "
06/12/1997 - "We studied the safety and efficacy of catheter-based intracoronary gamma radiation plus stenting to reduce coronary restenosis in patients with previous restenosis. "
08/01/2002 - "Catheter-based intracoronary radiation therapy using iridium-192 (Ir-192) has been shown to be effective in reducing recurrent coronary restenosis after initial percutaneous treatment of in-stent restenosis. "
06/01/2000 - "The SCRIPPS trial--catheter-based radiotherapy to inhibit coronary restenosis."
06/12/1997 - "In this preliminary, short-term study of patients with previous coronary restenosis, coronary stenting followed by catheter-based intracoronary radiotherapy substantially reduced the rate of subsequent restenosis."
01/19/1999 - "Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis."
08/05/1997 - "Recent studies have indicated that coronary restenosis after balloon angioplasty is the sum of geometric remodeling and neointimal formation. "
04/01/2013 - "Coronary restenosis, a major complication of percutaneous balloon angioplasty, results from neointimal proliferation of vascular smooth muscle cells (VSMCs). "
01/04/2006 - "Constrictive remodeling is thought to be more important than neointimal formation in coronary restenosis after balloon angioplasty. "
05/01/2001 - "[Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. "
01/25/2001 - "Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. "
07/18/2006 - "The cost-effectiveness ratio for PES in the study population compares reasonably with that for other treatments that reduce coronary restenosis, including alternative drug-eluting stent platforms."
06/28/2005 - "Published rates of coronary restenosis have fallen below 10% in drug-eluting stent trials. "
06/10/2015 - "Controlled Slow-Release Drug-Eluting Stents for the Prevention of Coronary Restenosis: Recent Progress and Future Prospects."
04/03/2015 - "The drug-eluting stent (DES) decreases the rate of coronary restenosis and re-obstruction. "
10/01/2011 - "Drug-eluting stents were developed to treat and prevent coronary restenosis. "